Exploring Kexing Biopharm's Global Impact at CPHI Milan 2026

From October 6 to 8, 2026, Kexing Biopharm participated in the CPHI Milan 2026 event, presenting its comprehensive drug pipeline and biosimilars developed in collaboration with various partners around the globe. This engagement allowed Kexing to connect with pharmaceutical buyers, biotech firms, and industry associates from various countries, thereby strengthening its international presence.

The company has made significant strides in establishing a mature overseas commercialization platform. It has successfully formed agreements for the overseas marketing of over 30 products with multiple domestic pharmaceutical companies. These products span therapeutic areas such as oncology, autoimmune disorders, and metabolic diseases, and Kexing's marketing outreach now extends to around 70 nations and regions. Impressively, the firm has submitted nearly 200 registration applications globally, which underscores its commitment to global health.

Among its key offerings is albumin-bound paclitaxel, which is already making waves in the European market, having been launched in the EU and the UK, with further expansions planned. This reflects Kexing's focus on meeting unmet clinical demands while also tapping into the region’s market potential.

In order to deepen its foothold in Europe, Kexing Biopharm has established a subsidiary in Germany and is progressing with plans to open subsidiaries in France, Spain, Italy, the UK, the Netherlands, and more. These local entities will allow Kexing Biopharm to cater to regional client needs effectively and forge enduring partnerships with various stakeholders. The company's consistent participation in CPHI events across Europe has proven valuable for nurturing its relationships with partners in the region.

Kexing Biopharm adopts an